Patents by Inventor Mark W. Riemen

Mark W. Riemen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Modified pseudomonas exotoxin PE.sub.40
    Patent number: 5912322
    Abstract: Psuedomonas exotoxin 40 is modified by deleting or substituting one or more cysteine residues. Such a modified protein may be incorporated into a fusion protein with TGF.alpha.. The resulting fusion protein exhibits altered biological activities from unmodified TGF.alpha.-PE.sub.40, including decreased cell killing activity and increase receptor-binding activity.
    Type: Grant
    Filed: April 14, 1997
    Date of Patent: June 15, 1999
    Assignee: Merck & Co., Inc.
    Inventors: Mark W. Riemen, Steven M. Stirdivant
  • Modified pseudomonas exotoxin PE.sub.40
    Patent number: 5621078
    Abstract: Pseudomonas exotoxin 40 is modified by deleting or substituting one or more cysteine residues. Such a modified protein, when hybridized to TGF.alpha., exhibits altered biological activities from unmodified TGF.alpha. PE.sub.40, including decreased cell killing activity and increased receptor-binding activity.
    Type: Grant
    Filed: February 21, 1995
    Date of Patent: April 15, 1997
    Assignee: Merck & Co., Inc.
    Inventors: Mark W. Riemen, Steven M. Stirdivant
  • DNA encoding immunogenic gpIII glycoprotein of varicella-zoster virus
    Patent number: 5306635
    Abstract: A gene of varicella-zoster virus (VZV) which encodes immunogenic outer surface viral proteins has been identified by DNA sequence analysis. Antibodies directed against peptides imputed from the DNA sequence can react with the glycoprotein, which itself is reactive with neutralizing antibodies. The amino-terminal sequence of the purified glycoprotein is identical to a portion of the amino acid sequence imputed from the DNA sequence. This glycoprotein is useful for the preparation of a vaccine against VZV.
    Type: Grant
    Filed: June 9, 1992
    Date of Patent: April 26, 1994
    Assignee: Merck & Co., Inc.
    Inventors: Paul M. Keller, Mark W. Riemen, Ronald W. Ellis, Andrew J. Davison, Robert S. Lowe
  • Gastrin releasing peptide antagonist
    Patent number: 5047502
    Abstract: Small cell lung carcinoma cells (SCLC) contain gastrin releasing peptide (GRP) receptors. The response of the cells to GRP is rapid growth. We have found a group of heptapeptides that act as GRP antagonists by blocking the binding of GRP to its receptor thereby inhibiting the growth of cells that are sensitive to the growth promoting acitivity of GRP.
    Type: Grant
    Filed: August 3, 1989
    Date of Patent: September 10, 1991
    Assignee: Merck and Co., Inc.
    Inventors: Allen I. Oliff, David C. Heimbrook, Mark W. Riemen, Victor M. Garsky
  • Gastrin releasing peptide antagonist
    Patent number: 5019647
    Abstract: Small cell lung carcinoma cells (SCLC) contain gastrin releasing peptide (GRP) receptors. The response of the cells to GRP is rapid growth. We have found a group of peptide derivatives that act as GRP antagonists by blocking the binding of GRP to its receptor thereby inhibiting the growth of cells that are sensitive to the growth promoting activity of GRP.
    Type: Grant
    Filed: May 24, 1988
    Date of Patent: May 28, 1991
    Assignee: Merck & Co., Inc.
    Inventors: Mark W. Riemen, Allen I. Oliff, Walfred S. Saari, David C. Heimbrook
  • Vaccine against varicella-zoster virus
    Patent number: 4952674
    Abstract: A gene of varicella-zoster virus (VZV) which encodes immunogenic outer surface viral proteins has been identified by DNA sequence analysis. Antibodies directed against peptides imputed from the DNA sequence can react with the glycoprotein, which itself is reactive with neutralizing antibodies. The amino-terminal sequence of the purified glycoprotein is identical to a portion of the amino acid sequence imputed from the DNA sequence. This glycoprotein is useful for the preparation of a vaccine against VZV.
    Type: Grant
    Filed: May 2, 1986
    Date of Patent: August 28, 1990
    Assignee: Merck & Co., Inc.
    Inventors: Paul M. Keller, Ronald W. Ellis, Robert S. Lowe, Mark W. Riemen, Andrew J. Davison
  • Gastrin releasing peptide antagonist
    Patent number: 4943561
    Abstract: Small cell lung carcinoma (SCLC) cells contain gastrin releasing peptide (GRP) receptors. The response of the cells to GRP is rapid growth. We have found a group of peptide derivatives that act as GRP antagonists by blocking the binding of GRP to its receptor thereby inhibiting the growth of cells that are sensitive to the growth promoting activity of GRP.
    Type: Grant
    Filed: November 28, 1988
    Date of Patent: July 24, 1990
    Assignee: Merck & Co., Inc.
    Inventors: David C. Heimbrook, Mark W. Riemen, Allen Oliff, Walfred S. Saari